Literature DB >> 11493939

Metformin-associated lactic acidosis in a low risk patient.

A K Ellis1, E A Iliescu.   

Abstract

Metformin is an oral hypoglycemic agent belonging to the class of biguanides that are commonly used in the treatment of type II diabetes mellitus. Lactic acidosis is a rare but severe adverse reaction that occurs primarily in patients with contraindications such as renal failure. The case of a 71-year-old woman with type II diabetes, in whom severe metformin-associated lactic acidosis was precipitated by acute renal failure in the absence of pre-existing chronic renal failure or other absolute contraindications to biguanide use, is presented. Aggressive correction of the acidosis and prolonged dialysis resulted in a favourable outcome despite severe acidosis. The present case report shows that metformin-associated lactic acidosis can occur in patients without pre-existing renal insufficiency. Metformin should be temporarily stopped when acute renal failure occurs or is anticipated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493939

Source DB:  PubMed          Journal:  Can J Clin Pharmacol        ISSN: 1198-581X


  4 in total

Review 1.  Metformin's contraindications should be contraindicated.

Authors:  James McCormack; Kevin Johns; Hugh Tildesley
Journal:  CMAJ       Date:  2005-08-30       Impact factor: 8.262

2.  The Association between Metformin Therapy and Lactic Acidosis.

Authors:  Isabelle H S Kuan; Ruth L Savage; Stephen B Duffull; Robert J Walker; Daniel F B Wright
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

3.  Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome.

Authors:  Juraporn Pongwecharak; Nawatsanan Tengmeesri; Nongluck Malanusorn; Matshamon Panthong; Nantida Pawangkapin
Journal:  Pharm World Sci       Date:  2009-05-22

4.  Clinical evaluation of Dyslipidemia among type II diabetic patients at Public hospital Penang, Malaysia.

Authors:  Nada F Zaki; Azhar S Sulaiman; Wasif S Gillani
Journal:  Int Arch Med       Date:  2010-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.